Webster Bank N. A. Acquires 60 Shares of Eli Lilly and Company (NYSE:LLY)

Webster Bank N. A. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.2% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,955 shares of the company’s stock after buying an additional 60 shares during the quarter. Webster Bank N. A.’s holdings in Eli Lilly and Company were worth $1,732,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Lynx Investment Advisory bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $32,000. LGT Financial Advisors LLC acquired a new position in Eli Lilly and Company in the 2nd quarter worth about $36,000. Redmont Wealth Advisors LLC acquired a new position in Eli Lilly and Company in the 1st quarter worth about $40,000. Morton Brown Family Wealth LLC increased its holdings in Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after purchasing an additional 15 shares in the last quarter. Finally, Richardson Financial Services Inc. acquired a new position in Eli Lilly and Company in the 4th quarter worth about $43,000. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, September 16th. Jefferies Financial Group upped their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. BMO Capital Markets upped their target price on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Finally, Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $979.29.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $21.37 during trading hours on Friday, hitting $932.06. 2,293,874 shares of the company’s stock traded hands, compared to its average volume of 3,009,544. The firm has a market cap of $885.83 billion, a P/E ratio of 137.27, a P/E/G ratio of 2.79 and a beta of 0.42. Eli Lilly and Company has a 52 week low of $547.61 and a 52 week high of $972.53. The business’s fifty day simple moving average is $910.84 and its two-hundred day simple moving average is $852.86. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, research analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.